Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N. Engl. J. Med.

Title: The New England journal of medicine

Publisher: New England Journal of Medicine (NEJM/MMS)

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Jul 07 2016

Volume: 375

Issue: 1

Affiliations

[1 ] From the Dean's Office, Dell Medical School, University of Texas, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat University Hospital and Medical School, Paris (P.A.); Stanford University Medical Center, Stanford Stroke Center, Palo Alto (G.W.A.), and the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E.) - both in California; AstraZeneca, Gothenburg, Sweden (H.D., P.H., J.J.); the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston (S.R.E.); the National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (K.M.); the Stroke Unit, Hospital Vall d'Hebron, Barcelona (C.A.M.); the Department of Neurology, Tiantan Hospital, Beijing (Y.W.); and the Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong (K.S.L.W.).

Article

DOI: 10.1056/NEJMoa1603060

PubMed ID: 27160892

SO-VID: 1555722a-d47f-4836-b1f7-604551ed9a8d

History

Data availability:

Comments

Comment on this article

scite_

Cited by 144

See all cited by